[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370284-105":59,"doc-detail-370284-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pi3k-specific-inhibitor-byl-719-synergizes-with-cisplatin-in-vitro-in-pik3ca-mutated-ovarian-cancer-cells","PI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells","","PI3K/Akt pathway targeting was evaluated in ovarian cancer models where peritoneal carcinomatosis and ascites favor multicellular aggregation and contribute to resistance to platinum salts. Using three ovarian cancer cell lines with distinct histology and mutations, PI3Kα inhibition with BYL-719 (alpelisib) markedly reduced Akt phosphorylation. In 3D aggregate cultures, cells showed greater resistance to BYL-719 and cisplatin than in 2D monolayers. Only PIK3CA-mutated SKOV-3 cells exhibited BYL-719/cisplatin synergy in 3D, producing strong cytotoxicity, and the combination remained active in 3D co-cultures with mesenchymal stem cells. These findings support prioritizing PI3Kα inhibition with cisplatin in PIK3CA-mutant advanced ovarian cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pi3k-specific-inhibitor-byl-719-synergizes-with-cisplatin-in-vitro-in-pik3ca-mutated-ovarian-cancer-cells/370284/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pi3k-specific-inhibitor-byl-719-synergizes-with-cisplatin-in-vitro-in-pik3ca-mutated-ovarian-cancer-cells/370284.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main therapeutic focus of the study?","Question",{"text":112,"@type":113},"The study focuses on targeting the PI3K/Akt signaling pathway by inhibiting PI3Kα using BYL-719 (alpelisib) in ovarian cancer models.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does BYL-719 affect PI3K/Akt signaling across tested cell lines?",{"text":117,"@type":113},"BYL-719 inhibits PI3K/Akt pathway activity in all tested ovarian cancer cell lines, causing a drastic reduction of Akt phosphorylation at serine 473.",{"name":119,"@type":110,"acceptedAnswer":120},"Does BYL-719 synergize with cisplatin, and under what culture conditions?",{"text":121,"@type":113},"BYL-719 synergizes with cisplatin in 3D cultures only in PIK3CA-mutated SKOV-3 cells, leading to major cytotoxicity in 3D aggregates.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370284,1790216815,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells  \nBenoît Thibault1,2􀀍, Adrien Thole1,2, Romina D’Angelo1,2, Céline Basset1,2,3 & Julie Guillermet-Guibert1,2􀀍  \nPeritoneal carcinomatosis in ovarian cancer is often associated with ascites where cancer cells  \ngrow as aggregates. Given the emerging evidence that multicellular growth enhances resistance to conventional therapies, and that patients frequently develop resistance to platinum salts, we investigated the efficiency of PI3K/Akt signalling pathway targeting in multicellular growth and its importance as a potential therapeutic target in cells resistant to platinum salts. Due to its importance in many cancers and to the frequent mutations of its encoding gene PIK3CA, we focused on targeting PI3Kα using BYL-719 (Alpelisib), an isoform-specific inhibitor already used in clinics. We used a panel of 3 ovarian cancer cell lines, SKOV-3, EFO-21 and OVCAR-3, which come from different histological origins and bear different mutations. PI3K targeting drugs inhibit the activity of the PI3K/Akt pathway in all tested ovarian cancer cell lines with a drastic reduction of the phosphorylation of Akt on theserine 473, regardless the histology or the mutational profile. We showed that when cultured in  \n3D aggregates, ovarian cancer cells are more resistant to the PI3Kα-specific inhibitor BYL-719 and cisplatin compared to 2D monolayers. BYL-719 synergizes with cisplatin in 3D cultures only in PIK3CAmutated SKOV-3 cells. This drug combination leads to a major cytotoxicity in 3D aggregates ofthis cell line. Finally, BYL-719 in combination with cisplatin remains active in 3D aggregates ofSKOV-3 cells co-cultured with mesenchymal stem cells. We have identified a signalling pathway of interest for the treatment of advanced ovarian cancer in vitro, which could limit the progression of this disease. These data pave the road to investigate whether PI3Kα-specific inhibitor BYL-719 should be proposed in combination with cisplatin, in priority in patients bearing a PIK3CA mutation.  \nKeywords PI3K signalling, Tumour cell aggregates, Resistance to treatment, Signal-targeted therapies, BYL- 719/Alpelisib, Cisplatin, Combination therapy, Mesenchymal stem cells  \nAbbreviations  \n3D Three-dimensional  \nCSC Cancer stem cell  \nEMT Epithelial-to-mesenchymal transition  \nEthD-1 Ethidium homodimer-1 GFP Green fluorescent protein  \nHER2 Human epidermal growth factor receptor-2 HIPEC Hyperthermic intraperitoneal chemotherapy PARP Poly (ADP-ribose) polymerase  \nPI3K Phosphoinositide 3-kinase  \nPIP2 Phosphatidylinositol-4,5-biphosphate MSC Mesenchymal stem cell  \n1CRCT, Université de Toulouse, Inserm, CNRS, Centre de Recherches en Cancérologie de Toulouse, Equipe SigDYN, 2 av Hubert Curien, Oncopole de Toulouse, Toulouse, France. 2Labex TOUCAN, ANR, Toulouse, France. 3Serviced’Anatomo-Pathologie, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), avenue Irène Joliot-Curie, Toulouse, France. 􀀍 email: [benoit.thibault@inserm.fr](benoit.thibault@inserm.fr); [julie.guillermet@inserm.fr](julie.guillermet@inserm.fr)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nBackground  \nIn 2022, 324,398 new cases of ovarian cancer were documented worldwide with 206,839 deaths1. This cancer is often associated with a poor prognosis due to the frequent intraperitoneal implantation of tumour cells, called peritoneal carcinomatosis, observed at advanced stages and the frequent acquisition of platinum salt resistance2,3. Found in around 89% of patients with stage III or IV ovarian cancer, massive production of ascites fluid (inflammatory exudate present in the peritoneal cavity) is in most cases associated with peritoneal carcinomatosis4. Unlike most solid cancers, ovarian cancer cells rarely migrate haematogeneously, but instead can disseminate by direct ext","cbCaisoyq7y4rMpm","https://ap.wps.com/l/cbCaisoyq7y4rMpm","pdf",4675587,11,"English","# Background\n## Multicellular 3D structures and chemotherapy resistance\n## Peritoneal carcinomatosis and platinum resistance\n## Rationale for targeted PI3K/Akt therapy","[{\"question\":\"What is the main therapeutic focus of the study?\",\"answer\":\"The study focuses on targeting the PI3K/Akt signaling pathway by inhibiting PI3Kα using BYL-719 (alpelisib) in ovarian cancer models.\"},{\"question\":\"How does BYL-719 affect PI3K/Akt signaling across tested cell lines?\",\"answer\":\"BYL-719 inhibits PI3K/Akt pathway activity in all tested ovarian cancer cell lines, causing a drastic reduction of Akt phosphorylation at serine 473.\"},{\"question\":\"Does BYL-719 synergize with cisplatin, and under what culture conditions?\",\"answer\":\"BYL-719 synergizes with cisplatin in 3D cultures only in PIK3CA-mutated SKOV-3 cells, leading to major cytotoxicity in 3D aggregates.\"}]","PI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells | PDF",1790187769,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3fb8fd8e6cb827b970f49fdf1b8496a4.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f733b780df54118107ac6648f37391c2.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23679aa442e991a7c539459df8da1472.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc826125627f039a91810d64e1629c56.webp",980,1287]